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Introduction
cost-effectiveness has become “the fourth hurdle” presented in 
front of the medicines in order to bring them to the market (10). 
Modeling is considered as vital part of the pharmacoeconomic 
studies. The model represents a simplified picture of reality, and 
is used when it is not possible to conduct economic evaluations 
parallel with the clinical study or is not possible to obtain long 
term data for the expected clinical results. the clinical trials for 
obtaining marketing authorization are focused on medicines 
safety and efficacy, and are not created with the intention of 
collecting data on costs, as well as on effectiveness. Most 
clinical studies has a limited number of comparative strategies 
(usually two, rarely more) and short follow-up (3). When costs 
or benefits of treatment occur over a long period of time, it is 
necessary to take into account the time preference for money 
and benefits. Discounting adjusts future costs and expresses all 
costs and monetary benefits in terms of their present value (8).
the purpose of this study was to present the effect of 
discounting on pharmacoeconomic model prepared for the 
cost-effectiveness evaluation of the different antihypertensive 
treatments in the prevention of cardiovascular disease (CVD) 
complications in primary care in Serbia. the study question 
was: what is the impact of discounting on the choice of cost-
effective therapeutic strategy?
Materials and Methods
Model and strategies
the therapy of the hypothetical cohort of 55 years old patients 
with hypertension (systolic and diastolic blood pressure ≥140 
and 90 mmHg, respectively), without other CVD complications 
or risk factors was modeled. comparator strategies were 
antihypertensive groups of medicines present in clinical 
practice (diuretic, beta blocker, calcium channel antagonist 
and Ace inhibitors). All therapeutic strategies were compared 
with strategy “no intervention”, to cover the patients who for 
any reason are not compliant with their therapy. combined 
therapy was modeled according to clinical practice (11), e.g. 
monotherapy with Ace inhibitor meant inclusion of diuretic 
(di-therapy) and beta blocker as tri-therapy.
A Markov model was constructed using the treeAge 
healthcare module version 1.5.2 (treeAge Software, inc., 
Williamstown, Massachusetts, USA). the model consists 
of 8 defined health states (Fig. 1) identical in structure to all 
strategies except for no intervention (due to no adherence to 
therapy, there are no mono-, di- or tri-therapy states). At the 
start patients are assumed not to have any cardiovascular co-
morbidity. the arrows show cohort movement through the 
model. At any point in time a patient can be in only one of 
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Discounting adjusts future costs and benefits in terms of their present value. The purpose of this study was to present the effect of 
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The Markov model consisting of eight states with the cycle length of six months was constructed. Comparator strategies were 
diuretic, beta blocker, calcium channel blocker and ACE inhibitors. All therapeutic strategies were compared with strategy “no 
intervention”. Complications of hypertension (acute myocardial infraction, angina pectoris or stroke alone or in combinations) 
and total mortality were observed as outcomes. Time horizon of the study was lifetime of the patient or 100 years old, due to 
assumption that 99% of the cohort would die at that age. Analyses were performed from the third-party payer perspective. 
Annual discount rate of 5% was applied at all future costs and effects.
Undiscounted results showed that patients who started treatment with a beta blocker had the highest life expectancy (49.00 
QALY) and being the most cost-effective strategy (ICER = €46.63/QALY compared to no intervention). In the case of discounting 
the highest gain in the QALY had patients who were on beta blocker, 23.7 QALY.  After the discounting cost-effective strategies 
were ACE inhibitor (ICER = €253.08/QALY compared to no intervention) and diuretic (ICER = €262.54/QALY compared to no 
intervention).
The results of the study showed that the discounting could change the choice of cost-effective therapeutic strategy.
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the states. The cycle length was defined to last 6 months and 
during this period a patient can be in only one of the defined 
states. the half-year length was chosen under the assumption 
that it is possible to have only one complication during that 
period, and that add-in therapy takes place every six months.
Fig. 1. Bubble diagram for health states in Markov model. * in case of no 
intervention there are no mono-, di- or tri-therapy. Ah – arterial hypertension; 
AMi – acute miocardial infraction; AP – angina pectoris.
complications of ht (AMi, AP or stroke alone or in 
combinations) and total mortality were observed as outcomes. 
Other CVD complications were not included in the model due 
to inadequate data in literature.
the time horizon of the study was the lifetime of the patient 
or 100 years old, due to assumption that 99% of the cohort 
would die at that age.
Probabilities
The transition of the patients through the model was defined 
by transition probabilities, describing the likelihood of 
moving within states over each model cycle. All probabilities 
were calculated from the large prospective studies, using the 
formula: p = 1 – exp {- rt}, where p is the probability, r is the 
rate and t is the time period of interest (1, 8).
Costs
Costs of medications, office visits to physicians, hospitalizations 
and surgical interventions were expressed in euro (€) using the 
average exchange rate during 2009 to convert Serbian dinar 
to € (€1 = 94.12 RSD) (4).  All costs were taken from the 
Republic Institute for Health Insurance (RIHI) price list and 
are summarized in Table 1. According to current legislation 
it is assumed that a patient has six visits to a GP and two, to 
a cardiologist per year. For base case analysis the medicines 
cost was for the most commonly used medicines from the 
given therapeutic class in the defined daily dose (e.g. enalapril 
20 mg daily). Drug utilization data were obtained from the 
RIHI. The costs for complications were calculated as a sum 
of hospitalization cost, cost of surgical intervention (cABG 
or PtcA) and costs for rehabilitation. Average numbers of 
hospital days spent at intensive care unit were 7.81, 9.06 and 
10.00 (6), while at rehabilitation the patients averagely spent 3, 
2 and 4 weeks per cycle for AMI, AP and stroke, respectively 
(expert opinion).
TAbLE 1
costs and utilities used in the model. All costs are presented in 
euro in 2009 values
Variable Value 
Cost per 6-month cycles Value (€)
diuretic (furosemide) 5.57
Beta blocker (metoprolol) 18.13
ca channel blocker (amlodipine) 19.97
Ace inhibitor (enalapril) 15.10
statins (simvastatin) 18.78
ticlopidine 60.22
clopidogrel 79.58
warfarin 11.32
acenocoumarol 7.05
hospital day (intensive cardiovascular surgery) 56.03
hospital day (general cardiovascular surgery) 20.88
rehabilition stroke – 1 day 12.22
rehabilition acute miocardial infraction/angina 
pectoris – 1 day 11.16
visit to general practictioner (every 2 months) 4.90
visit to cardiologist (once in 6 months) 1.99
acute miocardial infraction event 3204.23
angina pectoris event 3196.18
stroke event 2346.41
two or more complications 5831.21
Utility for the given state Value (QALY)
no intervention 0.8580
monotherapy with diuretic 0.9494
monotherapy with beta blocker 0.9998
monotherapy with ca channel blocker 0.8517
monotherapy with Ace inhibitor 0.9234
acute miocardial infraction 0.7571
angina pectoris 0.8567
stroke 0.6070
two or more complications 0.4750
death 0
Utilities
Utility measure included in the analysis was quality-adjusted 
life years (qAlY). qAlY can have values between 0 and 1, 
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where 0 represents death and 1 represents health state equal 
to perfect health. Due to unavailable utility values for Serbia, 
we obtained utility data from the harvard cost-effectiveness 
analysis registry database (2). in cases of combined therapy or 
two or more complications utility was obtained by multiplying 
individual utilities. Utility values used in the model are 
summarized in Table 1.
Cost-effectiveness analysis
Analyses were performed from the third-party payer 
perspective, RIHI, the leading health care payer, responsible 
for health care of almost the entire Serbian population (7.5 
million). Annual discount rate of 5% was applied at all future 
costs and effects (5).
Results and Discussion
the results from the undiscounted cost-effectiveness analysis 
are given in Table 2. the gain in qAlY in strategies that 
include a medicine was significantly higher than in the strategy 
of “no intervention”. Patients who started treatment with beta 
blocker had the highest life expectancy measured in 49 QALY, 
in the case of undiscounted results. After the incremental cost-
effectiveness analysis, strategies, diuretic and ca channel 
blocker were dominated, meaning that they had a negative gain 
in qAlY compared to the previous strategy (higher costs and 
lower effectiveness of the strategy). Strategy Ace inhibitor 
was extended dominated, meaning that the next strategy, beta 
blocker, was more effective (higher gain in qAlY) with the 
lower ICER value compared to ACE inhibitor.
the results from the pharmacoeconomic evaluation after 
the discounting of the costs and effects (the 5% per annum 
for both costs and effects) were different compared to the 
undiscounted results. in the case of discounting the highest 
gain in the qAlY had patients who were on beta blocker, 23.7 
qAlY. the results of the cost-effectiveness analysis for the 
discounted costs and effects are given in Table 3.
A)   
B)   
Fig. 2. Efficiency frontier for comparator strategies for treatment of patients 
with arterial hypertension: A) undiscounted results; b) discounted results 
(5%/year).
Graphical reperesentation of the undiscounted and 
discounted results is given in Fig. 2. the difference in results 
was seen on the efficiency frontier, which represents the 
TAbLE 2
Results for undiscounted costs and effects
Comparator cost (€) ∆ cost (€) effectiveness (QALY)
∆ effectiveness 
(QALY) C/E  (€/QALY) ICER (€/QALY)
no intervention 867.7 16.42 52.85
Ace inhibitor 2284.2 1416.5 45.98  29.56 49.68 47.92
Diuretic 2315.1 30.9 42.94 - 3.04 53.91 dominated
ca channel blocker 2372.0 87.8 39.95 - 6.03 59.37 dominated
Beta blocker 2386.8 102.6 49.00   3.02 48.72 33.97
TAbLE 3 
Results for discounted costs and effects (discount rate: 5% per year)
Comparator cost (€) ∆ cost (€) effectiveness (QALY)
∆ effectiveness 
(QALY) C/E  (€/QALY) ICER (€/QALY)
no intervention 484.7 11.67 41.53
Ace inhibitor 1000.6 515.8 13.71    2.03 72.98 253.08
Diuretic 1033.4 32.8 13.76    0.05 75.13 680.66
Beta blocker 1076.9 76.3 13.51 - 0.25 79.68 dominated
ca channel blocker 1092.1 15.3 11.25 - 2.51 97.10 dominated
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optimal strategies for treatment of hypertension. the slope of 
the frontier is the ICER value for the given strategy. In the case 
of the undiscounted results the efficiency frontier consisted 
of only two strategies: no intervention and beta blocker (Fig. 
2a). The efficiency frontier for discounted results (Fig. 2b) 
consisted of three strategies: no intervention, Ace inhibitor 
and beta blocker.
the results of this study showed great differences in 
the base-case analysis in the cost-effectiveness study, after 
discounting was employed. As shown in Table 2 and Table 
3, discounting increased the cost/qAlY ratio in all strategies 
that employed antihypertensive therapy (on average by 50%). 
it has been observed in earlier works that higher discount 
rates increased cost/qAlYs regardless of the intervention 
considered. lundkvist and collegues showed that cost/qAlY 
as a result of cost-effectiveness analysis in prevention of 
nonfatal stroke, was almost doubled after the discount rate 
changed from 0% to 5%, €8867/QALY vs. €16063/QALY, 
respectively (7).
interestiglly, the ranking of the strategies was changed 
after the discounting. in case of undiscounted results, only 
beta blocker was a cost-effective antihypertensive startegy 
(ICER value of €46.62/QALY), while in discounted results 
beta blocker was dominated by diuretic and Ace inhibitor. 
on the other hand, diuretic was a dominated strategy when the 
discount rate was 0%, but when the discount rate changed to 5% 
it had an ICER value of €680.66/QALY. This can be explanied 
by the fact that discounting dampens the relative importance 
of costs and benefits occurring in future. As discount rates 
rise, future benefits and costs become less and less important 
when compared with benefits and costs occurring at present. 
the effects of discounting are more pronounced for strategies 
where benefits (and/or cost offsets) occur later (9).
Conclusions
this study showed that discounting could change the choice 
of cost-effective therapeutic strategy and change the order in 
ranking of the antihypertensive strategies in the prevention of 
CVD complications.
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